The Boston Globe names Cubist to Globe 100's Top Places to Work '09

November 9, 2009 7:30 AM EST

Top-ranked life sciences company

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has been named one of the Top Places to Work in Massachusetts in the second annual employee-based survey from The Boston Globe. The Globe 100's Top Places to Work '09 magazine was published in the Sunday Globe on November 8th. Online, the report can be found at www.boston.com/topworkplaces. Cubist was ranked 37th on the overall list and is the top-ranked life sciences company on the list. Cubist also appeared on last year's inaugural list.

Produced by the same team that compiles the 22-year-old Globe 100 report of the best-performing public companies in Massachusetts, where Cubist ranked number one earlier this year, the Top Places to Work recognizes the most progressive companies in the state based on employee opinions about company leadership, compensation and training, diversity/inclusion, career development, family-friendly flexibility, and values and ethics. Private companies and nonprofits as well as publicly-held businesses were included in the analysis.

The rankings in the Globe 100's Top Places to Work are based on survey information collected by Workplace Dynamics, an independent company specializing in employee engagement and retention, from 86,000 employees at 269 Massachusetts organizations. This marks the second year that a Globe 100 report has honored private as well as publicly-held organizations.

Cubist President and CEO Michael Bonney said, "This recognition from the Boston Globe reaffirms what all of us at Cubist feel every day -- this is a great place to work! Our employees are committed to building the world's leading company focused on providing therapies for acutely ill patients. To ensure that mission's success, we depend on retaining and attracting the best and most highly motivated and committed scientific and business talent. Creating a positive work environment helps us achieve that end."

Steve Ainsley, the publisher of The Boston Globe, stated, "The companies included in the Globe 100's Top Places to Work have succeeded in creating a positive workplace for their employees in the midst of the uncertainties of the general economy. I congratulate each of them for an outstanding accomplishment."

To qualify for the Globe 100's Top Places to Work, a company must have more than 100 employees in Massachusetts. Nearly 600 qualified companies accepted an invitation to participate. Rankings were based on composite scores calculated purely on the basis of employee responses.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. In July 2008, Cubist entered into an agreement with AstraZeneca to promote their established antibiotic, MERREM(R) I.V. (meropenem for injection) in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials -- CONSERV(TM)-1 and CONSERV(TM)-2 -- for the reduction of blood loss during cardiac surgery, and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA), has a pre-IND program underway in novel treatments for respiratory syncytial virus (RSV) infections in children using Alnylam's RNA-interference (RNAi) technology. The RSV program also includes ALN-RSV01, for which Cubist has opt-in rights after Alnylam completes a Phase 2b study of ALN-RSV01 for the treatment of RSV infection in adult lung transplant patients. Cubist is headquartered in Lexington, MA. Additional information can be found at Cubist's web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of companies.

    Source: Cubist Pharmaceuticals, Inc.

Related Categories

Press Releases

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?